Additional trials studied the ideal sequencing of immune and targeted therapies for advanced BRAF mutated melanoma and have shown superiority in survival and response rates when ICI are used as first-line over BRAF/MEK targeted therapies [46]. This evidence concerns the gene MAP2K7 and melanoma.